News Pfizer's haemophilia B gene therapy meets phase 3 primary en... As December 2022 closed out, Pfizer announced positive top-
Views & Analysis Addressing market access obstacles for rare bleeding disorde... Scrutiniseing the market access situation for people with rare bleeding disorders.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
